Drug
apatinib plus camrelizumab
apatinib plus camrelizumab is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Recruiting2
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
unknown125%
completed125%
recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT05713994
recruiting
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
NCT05717738
unknownphase_2
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
NCT04586088
completedphase_2
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
NCT04642664
Clinical Trials (4)
Showing 4 of 4 trials
NCT05713994
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT05717738
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
NCT04586088Phase 2
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
NCT04642664Phase 2
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4